Trillium Therapeutics Inc (TRIL)
Trillium Therapeutics is a clinical stage immuno-oncology company developing therapies for the treatment of cancer. Co.'s primary program, TTI-621, is a SIRPaFc fusion protein that consists of the extracellular CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the Fc region of a human immunoglobulin G1 (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Co. is also developing a second SIRPaFc fusion protein, TTI-622, which consists of the extracellular CD47-binding domain of human SIRPa linked to a human immunoglobulin G4 Fc region, which has a decreased ability to engage Fc receptors than an IgG1 Fc.
|
Free TRIL Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.33 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|